Track Moderna, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Moderna, Inc. MRNA · Stock Open Moderna, Inc. in new tab

223.37 USD
EPS
-7.04
P/B
15.02
ROE
-34.50
Beta
1.17
Target Price
145.42 USD
Moderna, Inc. logo

Moderna, Inc.

🧾 Earnings Recap – Q3 2026

Moderna shares rose 5.3% after the company raised its 2026 revenue growth framework to 15%–25%, from up to 10%, citing stronger-than-expected U.S. and international revenue in Q3 and visibility into Q4. The quarter also showed a return to profitability, though some of the sales strength reflected shipment timing and cost of sales rose faster than revenue.

  • Q3 revenue was $1.3 billion, up 29% year over year; management reported $200 million in net income.
  • Full-year 2026 revenue growth framework increased to 15%–25%, versus the prior framework of up to 10%; the company still expects an approximately even U.S.-international split.
  • Q3 cost of sales was $318 million, or 24% of revenue, up 54% year over year, driven primarily by higher product sales volume and manufacturing-related costs.
  • R&D expense fell 27% year over year to $583 million, reflecting study wind-downs and organizational efficiencies.
  • Moderna ended the quarter with $8 billion in cash and investments, including net proceeds of approximately $2.6 billion from a convertible note financing.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 12, 2027
EPS-7.04
Book Value16.92
Price to Book15.02
Debt/Equity61.86
% Insiders7.356%
Growth
Revenue Growth0.29%
Estimates
Forward P/E-57.49
Forward EPS-4.42
Target Mean Price145.42

DCF valuation

Model fair value for Moderna, Inc. (MRNA)
Result
Sign in to run the valuation for MRNA.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
19 analysts · consensus Hold · mean target 145.42 USD (low 45.00, high 260.00) · as of 9 Nov 2026
Low 45.00
Mean 145.42
High 260.00
Price 223.37
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Moderna, Inc. Logo Moderna, Inc. Analysis (MRNA)

United States Health Care Official Website Stock

Is Moderna, Inc. a good investment? Moderna, Inc. (MRNA) is currently trading at 223.37 USD. Market analysts have a consensus price target of 145.42 USD. This suggests the asset is currently trading above analyst expectations.

Earnings Schedule: Moderna, Inc. is expected to release its next earnings report on Feb. 12, 2027. The market consensus estimate for Forward EPS is -4.42.

Investor FAQ

Does Moderna, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Moderna, Inc.?

Moderna, Inc. is classified as a Stock. You can compare it against 5 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 12, 2027. The company currently has a trailing EPS of -7.04.

Company Profile

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Exchange Ticker
SAO (Brazil) M1RN34.SA
NMS (United States) MRNA
FRA (Germany) 0QF.F
MEX (Mexico) MRNA.MX
MUN (Germany) 0QF.MU
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion